⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NVS News
Novartis AG
Novartis Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Novartis (NVS)
prnewswire.com
NVS
NVS SHAREHOLDER INVESTIGATION: Levi & Korsinsky Investigates Novartis AG for Possible Securities Law Violations
accessnewswire.com
NVS
LUXTURNA Sales Forecast and Market Size Analysis 2020-2034 | Innovative Reimbursement Models Expand Patient Access
globenewswire.com
NVS
Giant-Cell Arteritis - Market Insights, Epidemiology & Forecast to 2036 | Steroid-Sparing Therapies Reshape GCA Care
globenewswire.com
ABBV
NVS
KNSA
CHTR
Chronic Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Domain | DelveInsight
globenewswire.com
TLRY
TAK
TNDM
NVS
BMY
PFE
INCY
JNJ
AZN
MRK
ABBV
CRSP
SCLX
RIGL
JAZZ
GILD
REGN
AMGN
BIIB
PTGX
EXAS
SNOW
SRPT
VRTX
BNTX
ALKS
RGEN
IMUX
ADPT
ATRC
CRNX
CYTK
DTIL
EXEL
FGEN
GALT
GNTX
GRFS
GSK
HRMY
IDXX
ILMN
INSM
IONS
IRWD
KODK
LAKE
LULU
LYFT
MAR
MDLZ
MELI
MIRM
MNKD
MRNA
MTCH
NBIX
NCLH
NEM
NTRA
NVCR
ODFL
OMER
ORGO
OTEX
PACB
PBYI
PCAR
PEGA
PERI
PETS
PLRX
PMVP
PPC
PRGS
PRTA
PSNL
PTN
PZZA
QGEN
QTRX
RARE
RCEL
RDHL
RLAY
RLGT
RMD
ROST
RRX
RYAAY
RYTM
SAN
SBAC
SBRA
SEIC
SIGA
SIRI
SITE
SLAB
SLGN
SMCI
SMMT
SNPS
SNY
SOFI
SONO
SPCE
SSYS
STNG
STRA
STRL
STX
SWKS
SYK
SYNA
TCOM
TDOC
TECK
TEVA
TFX
TGTX
TIGR
TRMB
TRVG
TTWO
TUSK
TXRH
ULTA
UMC
UNFI
UNH
URBN
UTHR
VEEV
VELO
VERU
VIVO
VKTX
VLRS
VNDA
VRSK
VSAT
VTGN
WDC
WEC
WERN
WGO
WIX
WMB
WST
WTW
WYNN
XOM
XPER
XPO
XRAY
YETI
YRD
YUM
ZBRA
ZLAB
ZYME
Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Market Report 2026: Poised for Transformation Through 2036 as Pegcetacoplan, Iptacopan, and SGB-9768 Advance
globenewswire.com
APLS
BIIB
NVS
Graft Versus Host Disease (GvHD) Market & Epidemiology Forecast 2026-2036 - Set to Reach New Growth Milestones Through 2036 as Targeted, Cell-Based, and Microbiome Therapies Advance
globenewswire.com
ABBV
JNJ
SNY
INCY
SNDX
NVS
BMY
MRK
REGN
GILD
AMGN
BIIB
AZN
Focal Segmental Glomerulosclerosis (FSGS) Market Insights, Epidemiology and Forecast 2026-2036 - Targeted Therapies Reshape Treatment Through 2036
globenewswire.com
TARA
AMTX
AKBA
APLS
NVS
Complement 3 Glomerulopathy (C3G) Market Analysis Report 2026-2036 | Complement 3 Glomerulopathy Market Forecast to Reach Approximately $1 Billion by 2036 as Targeted Therapies Transform C3G Treatment
globenewswire.com
NVS
APLS
NVO
OMER
ARWR
Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)
globenewswire.com
NVS